Differential colorectal carcinogenesis:Molecular basis and clinical relevance
Colorectal cancer(CCR) is one of the most frequent cancers in developed countries.It poses a major public health problem and there is renewed interest in understanding the basic principles of the molecular biology of colorectal cancer.It has been established that sporadic CCRs can arise from at leas...
Saved in:
Published in | World journal of gastrointestinal oncology Vol. 2; no. 3; pp. 151 - 158 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
China
Baishideng Publishing Group Co., Limited
15.03.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Colorectal cancer(CCR) is one of the most frequent cancers in developed countries.It poses a major public health problem and there is renewed interest in understanding the basic principles of the molecular biology of colorectal cancer.It has been established that sporadic CCRs can arise from at least two different carcinogenic pathways.The traditional pathway,also called the suppressor or chromosomal instability pathway,follows the Fearon and Vogelstein model and shows mutation in classical oncogenes and tumour suppressor genes,such as K-ras,adenomatous polyposis coli,deleted in colorectal cancer,or p53.Alterations in the Wnt pathway are also very common in this type of tumour.The second main colorectal carcinogenesis pathway is the mutator pathway.This pathway is present in nearly 15% of all cases of sporadic colorectal cancer.It is characterized by the presence of mutations in the microsatellite sequences caused by a defect in the DNA mismatch repair genes,mostly in hMLH1 or hMSH2.These two pathways have clear molecular differences,which will be reviewed in this article,but they also present distinct histopathological features.More strikingly,their clinical behaviours are completely different,having the "mutator" tumours a better outcome than the "suppressor" tumours. |
---|---|
Bibliography: | Alberto Morán,Paloma Ortega,Carmen de Juan,Tamara Fernández-Marcelo,Cristina Frías,Pilar Iniesta,Manuel Benito,the second Department of Biochemistry and Molecular Biology,School of Pharmacy,Complutense University,28040-Madrid,Spain Andrés Sánchez-Pernaute,Antonio José Torres,Surgery Service II,Clínico San Carlos Hospital,28040-Madrid,Spain Eduardo Díaz-Rubio,Oncology Service,Clínico San Carlos Hospital,28040-Madrid,Spain Correspondence to: Manuel Benito, PhD, the second Department of Biochemistry and Molecular Biology, School of Pharmacy, Complutense University, 28040-Madrid, Spain. benito@farm.ucm.es Author contributions: Morán A, de Juan C, Frías C, Ortega P and Fernández-Marcelo T performed the molecular analyses; Sánchez-Pernaute A and Torres AJ assessed the clinical correlations; Díaz-Rubio E was assessor of this work; Benito M directed and coordinated this work; Benito M, Iniesta P and Morán A were involved in writing the manuscript. Telephone: +34-91-3941777 Fax: +34-91-3941779 |
ISSN: | 1948-5204 1948-5204 |
DOI: | 10.4251/wjgo.v2.i3.151 |